Literature DB >> 19129692

Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy.

A Christoforidou1, D Pantelidou, A Anastasiadis, A Goutzouvelidis, D Margaritis, I Kotsianidis, E Spanoudakis, V Kaloutsi, G Bourikas, C Tsatalas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19129692     DOI： 10.1159/000189381

Source DB:  PubMed          Journal:  Acta Haematol        ISSN： 0001-5792            Impact factor:   2.195


× No keyword cloud information.
  4 in total

1.  Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.

Authors:  Luigi Gugliotta; Carlos Besses; Martin Griesshammer; Claire Harrison; Jean-Jacques Kiladjian; Ruth Coll; Jonathan Smith; Brihad Abhyankar; Gunnar Birgegård
Journal:  Haematologica       Date:  2013-12-13       Impact factor: 9.941

2.  Development of a New Adult Sickle Cell Disease Center Within an Academic Cancer Center: Impact on Hospital Utilization Patterns and Care Quality.

Authors:  Biree Andemariam; Sasia Jones
Journal:  J Racial Ethn Health Disparities       Date:  2015-07-21

Review 3.  Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.

Authors:  Matjaz Sever; Kate J Newberry; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2014-03-17

4.  Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.

Authors:  Tomoki Ito; Yoshinori Hashimoto; Yasuhiro Tanaka; Aya Nakaya; Shinya Fujita; Atsushi Satake; Takahisa Nakanishi; Akiko Konishi; Masaaki Hotta; Hideaki Yoshimura; Kazuyoshi Ishii; Akiko Hashimoto; Toshinori Kondo; Hiromi Omura; Isaku Shinzato; Takayuki Tanaka; Shosaku Nomura
Journal:  Eur J Haematol       Date:  2019-06-17       Impact factor: 2.997
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.